Organization: Clairmark Investments Ltd

Leslie Dan increases Viventia stake

Viventia Biotech Inc has completed a paper transaction that will save the Toronto-based start-up more than $270,000 in interest payments. The funds will be used to finance ongoing R&D and corporate operations. Viventia — a developer of monoclonal antibodies targeting multiple forms of cancer — repaid a $2-million debenture to Clairmark Investments Ltd, which in…